Nov 23, 2020 Immunicum AB (publ) (IMMU.ST) announced that it has entered into an agreement with Van Herk Investments B.V. to acquire all of the shares

Immunicum är verksamma inom medicinteknik. Bolaget producerar terapeutiska vacciner som används inom onkologi. Bolaget driver huvudsakligen utveckling inom immunterapi med fokus på behandling av diverse allvarliga tumörer. Exempel på sjukdomar som produkter vidare används mot innefattar njur- och levercancer.

Learn more. Mar 16, 2021 Press Release. 16 March 2021. Immunicum AB (publ) Announces Updated Executive Management Team After Business Combination. Immunicum AB (IMMU) uses 0 email formats: . Enter a name to find & verify an email >>> Immunicum AB Market Cap as of today (February 08, 2021) is SEK1,194.74 Mil. In depth view into OSTO:IMMU Market Cap explanation, calculation, historical Immunicum AB. Last updated: 10.07.2019. company_picture.

Feb 9, 2021 Immunicum is planning to move its in-house research and process development activities into a new facility at the Leiden Bio Science Park. Dec 16, 2020 Immunicum AB (publ; IMMU.ST) published today the Company's financial calendar for the year of 2021. Year-End Report 2020, 18 February 2021 Nov 23, 2020 Immunicum AB (publ) (IMMU.ST) announced that it has entered into an agreement with Van Herk Investments B.V. to acquire all of the shares Dec 7, 2020 Immunicum AB receives Fast Track Designation (FTD) from the U.S. FDA for ilixadencel, for the treatment of Gastrointestinal Stromal Tumors. May 11, 2020 Immunicum AB has won an FDA RMAT for ilixadencel, its allogeneic dendritic cell immunotherapy against kidney cancer—the 43rd RMAT Mar 27, 2021 Every investor in Immunicum AB (publ) ( STO:IMMU ) should be aware of the most powerful shareholder groups Immunicum AB (publ) Publishes the Annual Report for 2020 12 Apr 2021; Immunicum Announces Investor Event and Conference Participation for April 07 Apr 2021; Notice of Annual General Meeting in Immunicum am (publ) 31 Mar 2021; See all The firm of the company is Immunicum AB (publ). The company is a public company (publ).”) to “Bolagets företagsnamn är Immunicum AB (publ). Bolaget är publikt (publ).“ (Eng. “The name of the Immunicum AB Immunicum AB is a biomedical company, which engages in the development of cancer immunotherapies.

IMMU | Complete Immunicum AB stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based Köp aktien Immunicum AB (IMMU). Hos Nordnet kan du handla från 0 kr i courtage.

In addition to his position as Co-Founder and CSO at Immunicum, he also serves as Associate Professor in Clinical Immunology at Uppsala University, Uppsala, Sweden, with special expertise in transplantation immunology and cancer immunotherapy and is former chairman …

OM IMMUNICUM AB (PUBL) Immunicum tillämpar sin framstående expertis i dendritcellsbiologi för att utveckla nya, lagringsbara (off-the-shelf), cellbaserade terapier för solida och blodburna tumörer. Om Immunicum AB (publ) Immunicum etablerar ett unikt angreppssätt inom immunonkologi genom utveckling av lagringsbara allogena cellbaserade terapier.

Immunicum AB har slutit ett avtal med Van Herk Investment B.V den 18 november om att förvärva samtliga aktier i DCPrime B.V. Köpeskillingen för aktierna i DCPrime ska erläggas genom att säljaren tecknar och tilldelas drygt 73 miljoner aktier i bolaget (73 909 635 aktier). 2021-04-08 2021-01-26 2021-04-12 2021-04-07 2 days ago 2021-03-26 Immunicum AB (publ) develops therapeutic cancer vaccines. Its lead product is ilixadencel, which is in Phase II clinical trial for the treatment of kidney cancer; and Phase Ib/II clinical trials 2021-04-12 Immunicum AB (1YG:MUN) set a new 52-week low during today's trading session when it reached 0.6945.
Apotekarprogrammet lund

About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies.

Pressmeddelande 3 april 2018 Immunicum AB (publ) lämnar uppdatering om det kliniska utvecklingsprogrammet för ilixadencel Immunicum AB (publ; IMMU.ST) lämnade idag en uppdatering gällande planerade, genomförda och tidigare slutförda kliniska studier för sitt ledande program, ilixadencel. Immunicum AB (publ) inleder forskningssamarbete med Icahn School of Medicine vid Mount Sinai: 12 Apr 2021: Immunicum AB (publ) offentliggör årsredovisning för 2020: 07 Apr 2021: Immunicum bjuder in till investerarmöte och meddelar deltagande i konferenser i april: 31 Mar 2021: KALLELSE TILL ÅRSSTÄMMA I IMMUNICUM AB (PUBL) 16 Mar 2021 Publiceringsdatum Utgivare Person i ledande ställning Befattning Närstående Karaktär Instrumentnamn ISIN Transaktionsdatum Volym Volymsenhet Pris Valuta Immunicum AB (publ) Presents Preclinical Data on Ilixadencel in Combination with Cancer Therapies and Immunotherapies at the 2020 Virtual ESMO Congress. Publicerad: 2020-09-17 (GlobeNewswire) Immunicum AB (publ) presenterar prekliniska data för ilixadencel i kombination med cancerbehandlingar och immunterapier på årets ESMO-kongress 2021-04-14 · About Immunicum AB (publ) Immunicum is leveraging its unparalleled expertise in dendritic cell biology to develop novel, off-the-shelf, cell-based therapies for solid and blood-borne tumors.
Aktivitetsbokningen stockholmsstad

case logic
samäganderätt fastighet
hur påverkar maten miljön
visma pressmeddelande
modellering og simulering
jobb eventbyrå

IMMUNICUM Aktiebolag,556629-1786 - På allabolag.se hittar du , bokslut, nyckeltal, styrelse, Status, adress mm för IMMUNICUM Aktiebolag

The Company currently has ongoing projects, with a strong focus on that which is based on the prioritized COMBIG 2021-04-12 08:59:54 Other information disclosed according to the rules of the Exchange, Immunicum AB (publ) Publishes the Annual Report for 2020. Immunicum is a clinical phase II company, develops cancer immunotherapies. Status Active; Last Funding Type Post-IPO Equity; Legal Name Immunicum AB. Jan 27, 2021 Immunicum AB (publ; IMMU.ST), the company that recently announced a business combination with DCprime B.V., has signed a long-term Immunicum AB (Nasdaq Stockholm: https://t.co/flpMTI73nE) is a clinical stage company developing novel #immunooncology therapies against a range of solid Latest Immunicum AB (IMMU:STO) share price with interactive charts, historical prices, comparative analysis, forecasts, business profile and more.

Ggmgastro com uk
lediga jobb kultur

Feb 9, 2021 Immunicum is planning to move its in-house research and process development activities into a new facility at the Leiden Bio Science Park.

Elivågor AB, 0,50%, 0,50%. Ivar Nordqvist, 0,50% 2020-12-22, Immunicum AB, Erik Manting, Annan ledande befattningshavare, Förvärv, Immunicum AB, SE0005003654, 2020-12-22, 530824, Antal, 7,28, SEK Immunicum AB har slutit ett avtal med Van Herk Investment B.V den 18 november om att förvärva samtliga aktier i DCPrime B.V. Köpeskillingen för aktierna i Hitta information om Immunicum AB. Adress: Östermalmstorg 5, Postnummer: 114 42. Telefon: 031-41 50 .. Få detaljerad information om Immunicum AB (IMMUN) aktie inklusive kurs, diagram, tekniska analyser, empirisk data, Immunicum AB rapporter och mycket mer. Immunicum AB (publ) offentliggör årsredovisning för 2020. Immunicum AB meddelar idag att årsredovisningen för 2020 nu finns tillgänglig på IMMUNICUM Aktiebolag,556629-1786 - På allabolag.se hittar du , bokslut, nyckeltal, styrelse, Status, adress mm för IMMUNICUM Aktiebolag.

Immunicum AB (publ) Presents Preclinical Data on Ilixadencel in Combination with Cancer Therapies and Immunotherapies at the 2020 Virtual ESMO Congress. Publicerad: 2020-09-17 (GlobeNewswire) Immunicum AB (publ) presenterar prekliniska data för ilixadencel i kombination med cancerbehandlingar och immunterapier på årets ESMO-kongress

Mar 16, 2021 Press Release. 16 March 2021.

Antalet anställda har minskat med 1 person sedan 2018 då det jobbade 12 personer på företaget. Bolaget är ett aktiebolag som varit aktivt sedan 2002. Immunicum AB omsatte 893 000 kr senaste räkenskapsåret (2019).